Informações de ADC Therapeutics SA

Mais detalhes de ADC Therapeutics SA Empresa

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.



Código da empresaADCT

Nome da EmpresaADC Therapeutics SA

Data de listagemMay 15, 2020

CEOMr. Ameet Mallik

Número de funcionários263

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 15

EndereçoBiopole

CidadeEPALINGES

Bolsa de valoresNYSE Consolidated

PaísSwitzerland

Código postal1066

Telefone41216530200

Sitehttps://adctherapeutics.com/

Código da empresaADCT

Data de listagemMay 15, 2020

CEOMr. Ameet Mallik

Executivos da empresa ADC Therapeutics SA



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.55M

-1.70%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

642.33K

+50.70%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

404.81K

+0.52%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

361.04K

-11.63%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

Ms. Viviane Monges

Non-Executive Independent Director

134.98K

+38.35%

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

99.40K

+38.06%

Mr. Robert W. (Bob) Azelby

Non-Executive Independent Director

55.26K

+98.35%

Mr. Timothy P. (Tim) Coughlin, CPA

Director

40.00K

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.55M

-1.70%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

642.33K

+50.70%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

404.81K

+0.52%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

361.04K

-11.63%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: qui, 2 de out

Investidores

Tipos de investidores

Investidores

Proporção

Redmile Group, LLC

13.93%

Prosight Capital

9.30%

HPWH TH AG

7.71%

Point72 Asset Management, L.P.

6.90%

OrbiMed Advisors, LLC

5.25%

Outro

56.91%

Investidores

Proporção

Redmile Group, LLC

13.93%

Prosight Capital

9.30%

HPWH TH AG

7.71%

Point72 Asset Management, L.P.

6.90%

OrbiMed Advisors, LLC

5.25%

Outro

56.91%

Tipos de investidores

Investidores

Proporção

Investment Advisor/Hedge Fund

22.78%

Hedge Fund

19.46%

Corporation

9.69%

Investment Advisor

9.20%

Research Firm

6.61%

Individual Investor

5.81%

Private Equity

5.25%

Bank and Trust

0.86%

Insurance Company

0.02%

Outro

20.31%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

184

72.23M

64.20%

+2.08M

2025Q2

209

87.64M

88.37%

-14.63M

2025Q1

217

80.51M

81.56%

-23.93M

2024Q4

219

81.03M

83.80%

-19.29M

2024Q3

223

79.78M

82.57%

-21.86M

2024Q2

215

76.61M

81.35%

-7.96M

2024Q1

177

59.13M

71.30%

-27.56M

2023Q4

169

58.32M

71.49%

-25.86M

2023Q3

180

68.48M

85.02%

-18.63M

2023Q2

182

74.11M

92.00%

-12.88M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Redmile Group, LLC

15.67M

13.93%

--

Jun 30, 2025

Prosight Capital

10.47M

9.3%

+924.77K

+9.69%

Jun 30, 2025

HPWH TH AG

8.67M

7.71%

-1.12M

-11.42%

May 15, 2025

Point72 Asset Management, L.P.

7.76M

6.9%

+7.76M

--

Jun 30, 2025

OrbiMed Advisors, LLC

5.91M

5.25%

-61.10K

-1.02%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.06M

3.6%

-442.92K

-9.85%

Jun 30, 2025

Oaktree Capital Management, L.P.

4.02M

3.57%

+4.02M

--

Apr 25, 2024

Morgan Stanley & Co. LLC

2.99M

2.66%

+33.76K

+1.14%

Jun 30, 2025

Heights Capital Management, Inc.

2.83M

2.52%

+2.83M

--

Jun 30, 2025

Nantahala Capital Management, LLC

2.27M

2.01%

+2.27M

--

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: seg, 6 de out

Nome

Proporção

iShares Micro-Cap ETF

0.05%

iShares Biotechnology ETF

0.02%

ProShares UltraPro Russell2000

0.01%

ProShares Hedge Replication ETF

0.01%

Proshares Ultra Russell 2000

0.01%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

0.01%

iShares Russell 2000 ETF

0.01%

Fidelity Enhanced Small Cap ETF

0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0%

Ver Mais

iShares Micro-Cap ETF

Proporção0.05%

iShares Biotechnology ETF

Proporção0.02%

ProShares UltraPro Russell2000

Proporção0.01%

ProShares Hedge Replication ETF

Proporção0.01%

Proshares Ultra Russell 2000

Proporção0.01%

iShares Russell 2000 Growth ETF

Proporção0.01%

Global X Russell 2000 ETF

Proporção0.01%

iShares Russell 2000 ETF

Proporção0.01%

Fidelity Enhanced Small Cap ETF

Proporção0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados